• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·France·Healthcare·EL.PA
Share

EssilorLuxottica Societe anonyme Stocks

€ 190.6Last Updated 09.11.2026

Issuer Rating

6/7
Performance

Favourable

Risk

Low

Recommendation

Buy

Market Cap

€ 99.22B

€ 190.6
Key Takeaways

Risk factor

Negligible price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Decent dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Latest news

21.10.2026 21:10

Shares of Ray-Ban had their best day since 2008. Should you buy them?

11.05.2026 14:27

At Armani's bequest: fashion house prepares to sell its 15% stake - media

31.03.2026 08:00

"Luxury's 'Magnificent Seven': UBS names stocks worth buying on the downturn

12.09.2025 22:41

Armani's will: the fashion designer allowed to sell his brand or go IPO

30.08.2025 16:01

Keep your eyes open: how AI and nostalgia are driving up eyewear sales

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

EssilorLuxottica S.A., established in Paris, France, in 1849, is a global enterprise dedicated to the design, production, and distribution of a wide range of ophthalmic products, including corrective lenses, eyewear frames, and sunglasses. The company extends its reach across North America, Europe, Latin America, Asia, Oceania, and Africa. Its operations are structured into five key divisions: Wholesale, Retail, Lenses and Optical Instruments, Equipment, and Sunglasses and Readers. The Wholesale division handles the manufacturing and large-scale distribution of luxury and performance eyewear. Conversely, the Retail segment is responsible for the direct sale of these premium and athletic vision products to consumers. The Lenses and Optical Instruments segment offers an extensive portfolio of advanced lens technologies, including Varilux progressive lenses, Crizal anti-reflective and anti-smudge coatings, Transitions photochromic lenses (featuring the latest Signature Gen 8), Eyezen lenses optimized for digital screen users, and Xperio polarized sun lenses, alongside corrective lens brands under license such as Nikon and Kodak. This segment also provides essential equipment like lens edging and mounting tools for opticians and laboratories, as well as optometry instruments for eye care professionals, educational bodies, military, and other organizations, while also developing digital platforms for online optical sales. The Equipment division supplies sophisticated digital surfacing and lens coating machinery to prescription laboratories, integrated optical networks, and lens manufacturers worldwide. Finally, the Sunglasses and Readers segment focuses on non-prescription eyewear, offering a diverse collection of sunglasses and reading glasses through various owned brands like Foster Grant, Magnivision, and Ryders Eyewear; licensed brands including Reebok, Steve Madden, Marvel, and Disney; and regional labels such as Bolon and Mujosh. EssilorLuxottica maintains a substantial operational network, encompassing 490 prescription laboratories and edging-mounting facilities. The company, initially known as Essilor International Société Anonyme, adopted its current name in October 2018.

Company Valuation

Slightly overvalued
3/7

Based on key historical and expected multiples, the stock is slightly overvalued relative to its peers. In particular, the stock is reasonably priced on P/E, of fair valu

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Somewhat favourable
5/7

The average target price of EL.PA is 209 and suggests 9.76% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recommendatio

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

10.11.2026 21:19

Analysts have begun lowering their price targets for Nvidia. Without Huang, the company could lose up to 30% of its value.

10.11.2026 19:53

U.S. stocks opened lower due to high inflation and expectations of a rate hike

10.11.2026 19:31

Shareholders have filed a lawsuit against Nvidia and Huang. What risks does the “key person” risk pose to the company?

10.11.2026 18:41

Inflation in the U.S. rose more than expected in October. What decision can we expect from the Fed?

10.11.2026 18:14

Investors have flocked to defensive stocks out of fear that the AI rally is coming to an end. Will this last?

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026